Amfecloral

Amfecloral is a historical appetite-suppressant drug rather than a naturally occurring or contemporary compound. Chemically it is the imine (Schiff base) produced when the primary amine of dextroamphetamine condenses with the aldehyde carbon of chloral, the anhydrous form of chloral hydrate. The resulting molecule, 2,2,2-trichloro-N-(1-phenylpropan-2-yl)ethanimine (CAS 5581-35-1), locks two pharmacologically active fragments into a single covalent structure through a hydrolytically labile carbon-nitrogen double bond.

Because that imine bond is readily cleaved under physiological conditions, amfecloral behaves as a prodrug that liberates its two parents on hydrolysis. One fragment is dextroamphetamine, the dextrorotatory enantiomer of amphetamine and the more potent releaser of dopamine and norepinephrine ^[1]. The other is chloral, which is rapidly reduced to trichloroethanol, the same active metabolite that gives chloral hydrate its sedative-hypnotic action through positive allosteric modulation of GABA-A receptors ^[5][6]. Amfecloral therefore represents a deliberate attempt to deliver a stimulant anorectic and a calming agent from one molecule.

Clinically, amfecloral was used as an anti-obesity agent and was marketed in the United States under the brand name Acutran. A 1970 review classified it as an anorectic with comparatively little stimulant activity, an observation consistent with the slow release of dextroamphetamine from the imine and the offsetting sedation supplied by the chloral moiety. The name amfecloral was adopted by the British Pharmacopoeia Commission in 1970.

The drug did not endure. Following the 1962 Kefauver-Harris Amendment, which raised efficacy standards, and the placement of amphetamines under strict control by the 1970 Controlled Substances Act, amphetamine-based diet aids came under intense regulatory pressure, and production of Acutran and its generic equivalents ceased in 1973. Amfecloral survives today only as a pharmacological curiosity.

Amfecloral is an obsolete, controlled-era anorectic and is not a current medicine; it should not be regarded as available or advisable for use. Its safety concerns are the sum of its two active moieties. The dextroamphetamine released carries the familiar amphetamine liabilities: elevated heart rate and blood pressure, arrhythmia risk, insomnia, anxiety, appetite and weight effects, dependence, and a meaningful potential for misuse and diversion.

The chloral, trichloroethanol component adds sedative-hypnotic risks, including central nervous system depression, next-day grogginess, and additive danger when combined with alcohol, benzodiazepines, opioids, or other GABAergic depressants. Pairing a stimulant with a sedative can also mask the subjective warning signs of overstimulation without removing the underlying cardiovascular strain. Chloral derivatives have their own historical toxicity profile, including gastric irritation and, with chronic use, concerns about cardiac and hepatic effects. None of this constitutes medical advice, and there is no established safe modern dosing.

Amfecloral emerged during the mid-twentieth-century enthusiasm for amphetamine-based diet drugs. It was patented around 1960 as an amphetamine prodrug intended to provide a smoother, more prolonged anorectic effect, and it reached the United States market as an anti-obesity product under the brand name Acutran. The strategy of tethering dextroamphetamine to chloral aimed to deliver appetite suppression while the co-released trichloroethanol tempered the stimulation; a 1970 review duly characterized amfecloral as an anorectic with little overt stimulant activity, and the British Pharmacopoeia Commission approved the name amfecloral that same year.

The regulatory climate soon turned against such agents. The 1962 Kefauver-Harris Amendment demanded proof of efficacy, and the 1970 Controlled Substances Act placed amphetamines under tight restriction amid mounting concern about the abuse of prescription diet pills. Under this pressure the amphetamine anorectics were progressively withdrawn, and production of Acutran and its generic equivalents ended in 1973. Amfecloral was never revived and has no place in modern pharmacotherapy.

Amfecloral is remembered as a clever but ultimately obsolete diet drug, a neat piece of medicinal-chemistry design that did not survive changing standards of efficacy and safety. The idea of fusing a stimulant anorectic with a sedative into a single hydrolyzable prodrug is genuinely elegant, and it anticipates the later logic of amphetamine prodrugs, yet in practice it offered no clear advantage over simpler agents and shared amphetamine's abuse and cardiovascular liabilities. Today it is essentially a historical curiosity of interest to pharmacology enthusiasts rather than a compound with any contemporary following or use.